Last reviewed 2026-05-14 · How we verify

Insulin Analog Mid Mixture

Eli Lilly and Company · FDA-approved active Small molecule

Insulin Analog Mid Mixture is a Insulin analog mixture Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.

This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic name	Insulin Analog Mid Mixture
Sponsor	Eli Lilly and Company
Drug class	Insulin analog mixture
Target	Insulin receptor
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

Insulin analog mid-mixture products combine rapid-acting and intermediate-acting insulin analogs in a fixed ratio to provide both immediate and sustained glucose control. The rapid-acting component begins working within minutes to address postprandial (after-meal) glucose spikes, while the intermediate-acting component provides basal insulin coverage over several hours. Together, they approximate the physiologic insulin secretion pattern in non-diabetic individuals.

Approved indications

Type 1 diabetes mellitus
Type 2 diabetes mellitus

Common side effects

Hypoglycemia
Weight gain
Injection site reactions
Lipodystrophy

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Insulin Analog Mid Mixture CI brief — competitive landscape report
Insulin Analog Mid Mixture updates RSS · CI watch RSS
Eli Lilly and Company portfolio CI

Frequently asked questions about Insulin Analog Mid Mixture

What is Insulin Analog Mid Mixture?

Insulin Analog Mid Mixture is a Insulin analog mixture drug developed by Eli Lilly and Company, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Insulin Analog Mid Mixture work?

This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.

What is Insulin Analog Mid Mixture used for?

Insulin Analog Mid Mixture is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Insulin Analog Mid Mixture?

Insulin Analog Mid Mixture is developed and marketed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

What drug class is Insulin Analog Mid Mixture in?

Insulin Analog Mid Mixture belongs to the Insulin analog mixture class. See all Insulin analog mixture drugs at /class/insulin-analog-mixture.

What development phase is Insulin Analog Mid Mixture in?

Insulin Analog Mid Mixture is FDA-approved (marketed).

What are the side effects of Insulin Analog Mid Mixture?

Common side effects of Insulin Analog Mid Mixture include Hypoglycemia, Weight gain, Injection site reactions, Lipodystrophy.

What does Insulin Analog Mid Mixture target?

Insulin Analog Mid Mixture targets Insulin receptor and is a Insulin analog mixture.

Drug class: All Insulin analog mixture drugs
Target: All drugs targeting Insulin receptor
Manufacturer: Eli Lilly and Company — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 1 diabetes mellitus
Indication: Drugs for Type 2 diabetes mellitus

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing